Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

14th St./Steelyard Commons will be closed through early November. April 28, the ramps from I-480 east to I-77 north & from I-480 west to I-77 south will be closed through early September.

Patients received nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) every 3 weeks for 4 cycles, followed by nivolumab (480 mg) every 4 weeks for up to 2 years. Patients received cabozantinib (40 mg ...

The FDA is conducting a priority review of nivolumab plus ipilimumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer. The FDA has accepted a ...

MG has sharpened prices for its ZS EV as the electric SUV enters runout mode, with new drive-away pricing that sees savings of up to $14,791. Stock of the entry-level Excite is already gone, and MG ...

Your browser does not support the audio element. The MG Comet Blackstorm edition has been launched at a price of Rs 7.80 lakh (ex-showroom), plus Rs 2.50 per km for ...

NORTH RIDGEVILLE, Ohio (WOIO) - A 28-year-old Mentor man was killed in a car crash on I-480 early Wednesday morning. North Ridgeville police said the accident happened just before 1 a.m. on I-480 ...

NORTH RIDGEVILLE, Ohio — A 28-year-old Mentor man has died following an overnight crash on I-480 West near the North Ridgeville city limits. North Ridgeville police say it was around 12:58 a.m ...

NORTH RIDGEVILLE, Ohio (WJW) – Several lanes of I-480 westbound were blocked overnight after a car crashed into the back of a disabled semi-truck. Pictures from the scene show the vehicle ...

A tragic event unfolded this morning on I-480 when a 28-year-old man from Mentor died in a vehicular collision. The crash occurred just before 1 a.m. westbound, near North Ridgeville's east city ...

The first seven-seat SUV sold by MG in Australia – the 2025 MG QS – has been revealed in government documents ahead of a local showroom arrival due by the middle of this year. But whereas the ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a decision expected by June 2025. The FDA accepted the supplemental biologics ...